Morning Poppers (My Book Has Launched Edition)

Good morning lads,

My god damned book is here. Be sure to toast it and leave a 5 star review into the Amazon ecosystem. I am exploring options to create a paperback and leatherbound version for those with rich libraries. In the meantime, the Kindle version will have to suffice.

Spain is down more than 1%. Chaos theory says Catalonions will break away from them, causing a civil war, at which time the EU will send shock troops in to restore order.

Gold is strong again, higher by 0.7% and WTI is +1%. Bitcoin is 4,800. I think I made a bet with someone that I’d cut off my genitalia should it go to 5,000. I don’t know why I always use my testicles in bets. There is really no upside to this way of thinking.

Nasdaq futures are +13. You can’t stop the fire.

Here are some notable movers in the pre-market, per Briefing.

UAL +4.3%, (provides Q3 investor update; raised its Q3 pre-tax margin guidance and updated other metrics)
WMT +2.3%, (reaffirms FY18 guidance; sees FY19 EPS +5% with sales up at or above 3%; adds to share buyback)
REVG +1.1%

USEG +25.8% (sale of certain non-operated Williston Basin assets; received $2.0 million in cash)
PFE +1% (reviewing strategic alternatives for its Consumer Healthcare business)
HON +0.7% (announces planned comprehensive portfolio review)

KALV +75.4% (enters collaboration agreement with Merck (MRK); Merck to pay $37 mln upfront payment, additionally take 9.9% stake through private placement at $8.50/share)
ANAB +57.1% (announces positive proof-of-concept data for ANB020)
PSDV +12.3% (enters strategic collaboration agreement with Nicox to develop sustained release drug to lower intraocular pressure in patients with glaucoma)
REPH +10.6% (presents clinical efficacy data from its Phase III study evaluating intravenous (IV) meloxicam 30mg)
OVID +8.2% (receives orphan drug designation from the U.S. FDA for OV101)
ICHR +5.9% (entered into ‘substantial’ agreement to produce liquid delivery systems for one of its key customers)
NVDA +4.2% (announces new Drive PX Pegasus AI hardware that enables fully autonomous (level 5) driving – TechCrunch)
ATRS +4% (enters into a definitive asset purchase agreement to sell the worldwide rights, including certain fixed assets, for the ZOMAJET )
ALDX +2.6% (announces new clinical data for ADX-102 from recently completed Phase 2 clinical trials of dry eye disease and allergic conjunctivitis), CLVS +1.8% ( submitted sNDA to the FDA for rucaparib as maintenance treatment of patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy)
DXC +1.2% (to acquire Logicalis SMC)
REVG +1.1% (announces an underwritten public offering of 10,000,000 shares of common stock by certain selling stockholders)
AGN +1% (FDA has accepted the NDA for ulipristal acetate)

ABEO +4% (initiated with a Buy at Citigroup)
PANW +2.8% (upgraded to Overweight from Equal-Weight at Morgan Stanley)
RBS +2.5% (upgraded to Neutral from Underperform at Credit Suisse; upgraded to Neutral from Sell at Citigroup)
RIG +1.6% (initiated with Buy ratings at Deutsche Bank)
TSM +1.5% (upgraded to Overweight from Neutral at JP Morgan)
DVN +1.4% (upgraded to Buy at Jefferies)
DO +1.3% (upgraded to Neutral from Sell at FBR & Co)
TSLA +1.2% (target raised to $379 from $317 at Morgan Stanley)
LYG +0.8% (upgraded to Outperform from Neutral at Credit Suisse)
CXO +0.8% (upgraded to Buy at Jefferies)
CAT +0.7% (target raised to $158 at Goldman – new street high)
CLB +0.7% (initiated with Buy ratings at Deutsche Bank)
HAL +0.5% (initiated with Buy ratings at Deutsche Bank)

How about them semis?